Browse Category: Treatment

Eric Lefkofsky And Tempus Labs At The Forefront Of Cancer Treatment

“At some point, the dream is so intoxicating that I’m compelled to do everything in my power to make the dream a reality.” These poignant words summarize the mission of Eric Lefkofsky, which is to fight cancer using data analytics to revolutionize cancer medicine. In 2015, Eric Lefkofsky co-founded and currently serves as the Chief Executive Officer of Tempus Labs, a Chicago-based health and biotech company that utilizes data science to help eradicate cancer through transformative advances in science. Tempus Labs developed two biotechnologies used for the treatment of diseases previously thought to be untreatable.

Tempus Labs developed the ability to sequence the genome of a person living with cancer and understands how to fight cancer utilizing the human immune system. Tempus Labs and a team of 150 immunologists, geneticists, and computational biologists in collaboration with data scientists and engineers work to answer the question: Why do some patients respond well to a cancer therapy while others do not? Tempus Labs responded to that query by building an operating system to fight cancer. The work of the team at Tempus Labs facilitates the delivery of personalized cancer care through an interactive analytical and machine learning platform. Tempus Labs empowers physicians to make data-driven, real-time decisions to benefit their cancer patients.

The goal of Eric Lefkofsky and Tempus Labs is to ensure each cancer patient benefits from the treatment of others by providing physicians with the tools and data they can use. In addition to the development of an operating system to combat cancer, Tempus Labs is building the world’s most extensive library of molecular and clinical data. Tempus Labs works collaboratively with many of the National Cancer Institute’s comprehensive cancer centers located in the United States, and they have collaborated with several colleges and university. Tempus Labs has raised $130 million in funding.

To Read More Click Here